No topic is getting as much attention right now as generative artificial intelligence. And that is also true in drug discovery.
At STAT Breakthrough Summit West, we'll be putting this exponentially improving technology under the microscope to examine its potential in one of the toughest areas known to humankind— drug discovery.
Putting medicine in a body is as tough as putting a person on the moon.
We'll look at the potential for this to change, with fireside chats with three of the major players in the space: the top health executives at Microsoft, at chip behemoth NVIDIA, and Isomorphic Labs, the drug discovery spinout of Google Deepmind. The latter two will be guided by STAT's award-winning AI observer, Casey Ross.
And the day will wrap up with a critical look at what's possible from AI pioneers Daphne Koller, now CEO of insitro, and Vijay Pande, now a venture capitalist at a16z. They'll be joined by star pharma blogger Derek Lowe, who has been skeptical of AI's potential, and I will moderate. We promise to give you new insight into what this emerging field does and doesn't mean for the business of inventing and developing drugs.
Matthew Herper X: @matthewherper Editorial Director, Events
Request an in-person invitation to join us in SF
Applications to attend Breakthrough West in-person are still open. Apply through the brief form linked below to request an invitation.
.jpg?width=1120&upscale=true&name=24%20BSW%20Sponsor%20Lock%20Up%20(2).jpg)
No comments